Literature DB >> 20721523

[Treatment of metastatic melanoma with CTLA4 antibodies].

C Hafner1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20721523     DOI： 10.1007/s00105-010-2033-5

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


× No keyword cloud information.
  2 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

2.  Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy.

Authors:  Kaan Harmankaya; Christa Erasim; Claus Koelblinger; Ramy Ibrahim; Axel Hoos; Hubert Pehamberger; Michael Binder
Journal:  Med Oncol       Date:  2010-07-01       Impact factor: 3.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.